BioCentury
ARTICLE | Strategy

Two heads are better

What Novartis needs to do beyond reorganization to grow innovation

May 23, 2016 7:00 AM UTC

With Gleevec imatinib off patent, flagging ophthalmics sales and at least one slower than expected launch, Novartis AG is consolidating operations at the top to cut costs, while also splitting its R&D into two buckets: cancer and "other."

The pharma has already shored up much of its early and late stage oncology pipeline, but will need to do the same across many of its other disease areas...